Clopidogrel response variability is associated with endothelial dysfunction in coronary artery disease patients receiving dual antiplatelet therapy

Atherosclerosis

Volumn 242, Issue 1, 2015, Pages 102-108

  Siasos, Gerasimos ^a,b   Oikonomou, Evangelos ^a   Zaromitidou, Marina ^a,b   Kioufis, Stamatios ^a   Kokkou, Eleni ^a   Mourouzis, Konstantinos ^a   Vlasis, Konstantinos ^a   Vavuranakis, Manolis ^a   Stone, Peter H ^b   Papavassiliou, Athanasios G ^a   Tousoulis, Dimitris ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Atherosclerosis; Clopidogrel; Coronary artery disease; Endothelial function; Platelet function tests; Platelet reactivity

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; ANTITHROMBOCYTIC AGENT; CYP2C19 PROTEIN, HUMAN; CYTOCHROME P450 2C19; PURINERGIC P2Y RECEPTOR ANTAGONIST; TICLOPIDINE;

ADULT; AGED; ARTICLE; BODY MASS; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DYSLIPIDEMIA; ENDOTHELIAL DYSFUNCTION; FEMALE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; PLATELET REACTIVITY; PRIORITY JOURNAL; THROMBOCYTE FUNCTION ANALYZER; TREATMENT RESPONSE; ANALOGS AND DERIVATIVES; BLOOD; BLOOD CLOTTING PARAMETERS; BRACHIAL ARTERY; COMBINATION DRUG THERAPY; COMPARATIVE STUDY; CORONARY DISEASE; DRUG POTENTIATION; GENETICS; GENOTYPE; HYPERLIPIDEMIAS; METABOLIC ACTIVATION; MIDDLE AGED; OBESITY; PATHOPHYSIOLOGY; POSTOPERATIVE COMPLICATIONS; PROSPECTIVE STUDY; RISK FACTOR; SMOKING; STENT; THROMBOPHILIA; VASCULAR ENDOTHELIUM; VASODILATATION;

ACTIVATION, METABOLIC; AGED; ASPIRIN; BRACHIAL ARTERY; CORONARY DISEASE; CYTOCHROME P-450 CYP2C19; DIABETES MELLITUS; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; ENDOTHELIUM, VASCULAR; FEMALE; GENOTYPE; HUMANS; HYPERLIPIDEMIAS; MALE; MIDDLE AGED; OBESITY; PERCUTANEOUS CORONARY INTERVENTION; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; POSTOPERATIVE COMPLICATIONS; PROSPECTIVE STUDIES; PURINERGIC P2Y RECEPTOR ANTAGONISTS; RISK FACTORS; SMOKING; STENTS; THROMBOPHILIA; TICLOPIDINE; VASODILATION;

EID: 84937047098     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2015.07.009     Document Type: Article

References (48)

1. Melloni C., Jones W.S., Washam J.B., et al. Antiplatelet and Anticoagulant Treatments for Unstable Angina/Non-ST Elevation Myocardial Infarction 2013, Rockville (MD).
2. Patti G., Nusca A., Mangiacapra F., Gatto L., D'Ambrosio A., Di Sciascio G. Point-of-care measurement of clopidogrel responsiveness predicts clinical outcome in patients undergoing percutaneous coronary intervention results of the ARMYDA-PRO (antiplatelet therapy for reduction of myocardial damage during angioplasty-platelet reactivity predicts outcome) study. J.Am. Coll. Cardiol. 2008, 52:1128-1133.
3. Price M.J., Berger P.B., Teirstein P.S., et al. Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA 2011, 305:1097-1105.
4. Tousoulis D., Siasos G., Zaromytidou M., et al. The role of the cytochrome P450 polymorphisms in clopidogrel efficacy and clinical utility. Curr. Med. Chem. 2011, 18:427-438.
5. Tousoulis D., Siasos G., Zaromitidou M., et al. The impact of CYP2C19 genotype on cardiovascular events and platelet reactivity in patients with coronary artery disease receiving clopidogrel. Int. J. Cardiol. 2013, 168:1594-1596.
6. Tousoulis D., Kioufis S., Siasos G., et al. The impact of AMPD1 gene polymorphism on vascular function and inflammation in patients with coronary artery disease. Int. J. Cardiol. 2014, 172:e516-518.
7. Pare G., Mehta S.R., Yusuf S., et al. Effects of CYP2C19 genotype on outcomes of clopidogrel treatment. N.Engl. J. Med. 2010, 363:1704-1714.
8. Oikonomou E., Papageorgiou N., Papaioannou S., et al. Genetic testing and antiplatelet treatment: still way to go?. Int. J. Cardiol. 2015, 187:63-65.
9. Siasos G., Tousoulis D., Stefanadis C. Multiple mechanisms affect the clopidogrel response. J.Am. Coll. Cardiol. 2009, 53:900-901. author reply 901.
10. Schachinger V., Britten M.B., Zeiher A.M. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation 2000, 101:1899-1906.
11. Davi G., Patrono C. Platelet activation and atherothrombosis. N.Engl. J. Med. 2007, 357:2482-2494.
12. Tantry U.S., Gesheff M., Liu F., Bliden K.P., Gurbel P.A. Resistance to antiplatelet drugs: what progress has been made?. Expert Opin. Pharmacother. 2014, 15:2553-2564.
13. Gurbel P.A., Bliden K.P., Hiatt B.L., O'Connor C.M. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 2003, 107:2908-2913.
14. Tantrye U.S., Gurbel P.A. Antiplatelet drug resistance and variability in response: the role of antiplatelet therapy monitoring. Curr. Pharm. Des. 2013, 19:3795-3815.
15. Tousoulis D., Antoniades C., Stefanadis C. Evaluating endothelial function in humans: a guide to invasive and non-invasive techniques. Heart 2005, 91:553-558.
16. Campo G., Parrinello G., Ferraresi P., et al. Prospective evaluation of on-clopidogrel platelet reactivity over time in patients treated with percutaneous coronary intervention relationship with gene polymorphisms and clinical outcome. J.Am. Coll. Cardiol. 2011, 57:2474-2483.
17. Song H., Bu G. MicroRNA-205 inhibits tumor cell migration through down-regulating the expression of the LDL receptor-related protein 1. Biochem. Biophys. Res. Commun. 2009, 388:400-405.
18. von Beckerath N., Pogatsa-Murray G., Wieczorek A., Sibbing D., Schomig A., Kastrati A. Correlation of a new point-of-care test with conventional optical aggregometry for the assessment of clopidogrel responsiveness. Thromb. Haemost. 2006, 95:910-911.
19. Bhatt D.L., Pare G., Eikelboom J.W., et al. The relationship between CYP2C19 polymorphisms and ischaemic and bleeding outcomes in stable outpatients: the CHARISMA genetics study. Eur. Heart J. 2012, 33:2143-2150.
20. Mega J.L., Close S.L., Wiviott S.D., et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N.Engl. J. Med. 2009, 360:354-362.
21. Chen M., Liu X.J., Yan S.D., et al. Association between cytochrome P450 2C19 polymorphism and clinical outcomes in Chinese patients with coronary artery disease. Atherosclerosis 2012, 220:168-171.
22. Parodi G., Marcucci R., Valenti R., et al. High residual platelet reactivity after clopidogrel loading and long-term cardiovascular events among patients with acute coronary syndromes undergoing PCI. JAMA 2011, 306:1215-1223.
23. Siasos G., Tousoulis D., Stefanadis C. CYP2C19 genotype and cardiovascular events. JAMA 2012, 307:1483-1484. author reply 1484-1485.
24. Heitzer T., Rudolph V., Schwedhelm E., et al. Clopidogrel improves systemic endothelial nitric oxide bioavailability in patients with coronary artery disease: evidence for antioxidant and antiinflammatory effects. Arterioscler. Thromb. Vasc. Biol. 2006, 26:1648-1652.
25. Patti G., Grieco D., Dicuonzo G., Pasceri V., Nusca A., Di Sciascio G. High versus standard clopidogrel maintenance dose after percutaneous coronary intervention and effects on platelet inhibition, endothelial function, and inflammation results of the ARMYDA-150 mg (antiplatelet therapy for reduction of myocardial damage during angioplasty) randomized study. J.Am. Coll. Cardiol. 2011, 57:771-778.
26. Malek L.A., Grabowski M., Spiewak M., et al. Relation between impaired antiplatelet response to clopidogrel and possible pleiotropic effects. J.Thromb. Thrombolysis 2007, 24:301-305.
27. Angiolillo D.J., Fernandez-Ortiz A., Bernardo E., et al. Clopidogrel withdrawal is associated with proinflammatory and prothrombotic effects in patients with diabetes and coronary artery disease. Diabetes 2006, 55:780-784.
28. Woo J.S., Kim W., Jang H.H., Kim J.B., Kim W.S., Kim K.S. Effect of platelet reactivity, endothelial function, and inflammatory status on outcomes in patients with stable angina pectoris on clopidogrel therapy. Am. J. Cardiol. 2014, 113:786-792.
29. Vaturi M., Vaduganathan M., Bental T., Solodky A., Kornowski R., Lev E.I. Relation of aspirin response to age in patients with stable coronary artery disease. Am. J. Cardiol. 2013, 112:212-216.
30. Cuisset T., Quilici J., Grosdidier C., et al. Comparison of platelet reactivity and clopidogrel response in patients 75 years undergoing percutaneous coronary intervention for non-ST-segment elevation acute coronary syndrome. Am. J. Cardiol. 2011, 108:1411-1416.
31. Gremmel T., Steiner S., Seidinger D., Koppensteiner R., Panzer S., Kopp C.W. Adenosine diphosphate-inducible platelet reactivity shows a pronounced age dependency in the initial phase of antiplatelet therapy with clopidogrel. J.Thromb. Haemost. 2010, 8:37-42.
32. Silvain J., Cayla G., Hulot J.S., et al. High on-thienopyridine platelet reactivity in elderly coronary patients: the SENIOR-PLATELET study. Eur. Heart J. 2012, 33:1241-1249.
33. Chirumamilla A.P., Maehara A., Mintz G.S., et al. High platelet reactivity on clopidogrel therapy correlates with increased coronary atherosclerosis and calcification: a volumetric intravascular ultrasound study. JACC Cardiovasc. Imaging 2012, 5:540-549.
34. Mangiacapra F., De Bruyne B., Muller O., et al. High residual platelet reactivity after clopidogrel: extent of coronary atherosclerosis and periprocedural myocardial infarction in patients with stable angina undergoing percutaneous coronary intervention. JACC Cardiovasc. Interv. 2010, 3:35-40.
35. Angiolillo D.J. Antiplatelet therapy in diabetes: efficacy and limitations of current treatment strategies and future directions. Diabetes Care 2009, 32:531-540.
36. Huxley R., Barzi F., Woodward M. Excess risk of fatal coronary heart disease associated with diabetes in men and women: meta-analysis of 37 prospective cohort studies. BMJ 2006, 332:73-78.
37. Hathcock J.J. Flow effects on coagulation and thrombosis. Arterioscler. Thromb. Vasc. Biol. 2006, 26:1729-1737.
38. Stone P.H., Saito S., Takahashi S., et al. Prediction of progression of coronary artery disease and clinical outcomes using vascular profiling of endothelial shear stress and arterial plaque characteristics: the PREDICTION study. Circulation 2012, 126:172-181.
39. Massberg S., Schurzinger K., Lorenz M., et al. Platelet adhesion via glycoprotein IIb integrin is critical for atheroprogression and focal cerebral ischemia: an invivo study in mice lacking glycoprotein IIb. Circulation 2005, 112:1180-1188.
40. Massberg S., Brand K., Gruner S., et al. Acritical role of platelet adhesion in the initiation of atherosclerotic lesion formation. J.Exp. Med. 2002, 196:887-896.
41. Fateh-Moghadam S., Li Z., Ersel S., et al. Platelet degranulation is associated with progression of intima-media thickness of the common carotid artery in patients with diabetes mellitus type 2. Arterioscler. Thromb. Vasc. Biol. 2005, 25:1299-1303.
42. Weidinger F., Glogar D., Sochor H., Sinzinger H. Platelet survival in patients with dilated cardiomyopathy. Thromb. Haemost. 1991, 66:400-405.
43. Andreassen A.K., Nordoy I., Simonsen S., et al. Levels of circulating adhesion molecules in congestive heart failure and after heart transplantation. Am. J. Cardiol. 1998, 81:604-608.
44. Israels S.J., McNicol A., Dean H.J., Cognasse F., Sellers E.A. Markers of platelet activation are increased in adolescents with type 2 diabetes. Diab. Care 2014, 37:2400-2403.
45. Hess K., Grant P.J. Inflammation and thrombosis in diabetes. Thromb. Haemost. 2011, 105(Suppl.1):S43-S54.
46. Ferreiro J.L., Gomez-Hospital J.A., Angiolillo D.J. Platelet abnormalities in diabetes mellitus. Diab. Vasc. Dis. Res. 2010, 7:251-259.
47. Morel O., Kessler L., Ohlmann P., Bareiss P. Diabetes and the platelet: toward new therapeutic paradigms for diabetic atherothrombosis. Atherosclerosis 2010, 212:367-376.
48. Kitta Y., Obata J.E., Nakamura T., et al. Persistent impairment of endothelial vasomotor function has a negative impact on outcome in patients with coronary artery disease. J.Am. Coll. Cardiol. 2009, 53:323-330.